Scholar Rock Holding Corp
apitegromab
spinal muscular atrophy
Resolved
280days ago
FDA decision · ~ Sep 30, 2025 estimated
What's at stake
An FDA complete response letter on apitegromab for spinal muscular atrophy is in focus around ~ Sep 30, 2025.
Primary source
· SEC 8-K
verified 15h ago
“Scholar Rock plans to resubmit the apitegromab BLA following a successful reinspection of the site.”